Products in GSK Pipeline: Continuing to Advance
Darapladib, an Lp-PLA2 inhibitor discovered by GSK based on HGS technology, is currently in Phase 2/3 development by GSK for use in the treatment of atherosclerosis. HGS will receive a 10% royalty on worldwide sales of darapladib if it is commercialized, and has a 20% co-promotion option in North America and Europe.
In May 2007, GSK advanced Syncria(R) (albiglutide), formerly known as Albugon(TM), to Phase 2b development for the treatment of diabetes. Syncria is an albumin-fusion protein created by HGS using the Company's proprietary albumin-fusion technology. HGS licensed Syncria to GSK and is entitled to fees and milestone payments, some of which have already been received, that could amount to as much as $183 million, in addition to royalties on worldwide sales if Syncria is commercialized.
HGS management will hold a conference call to discuss this announcement today at 11 AM Eastern. Investors may listen to the call by dialing (800) 909- 5202 or (785) 830-7975, passcode 9942874, five to 10 minutes prior to the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing (888) 203-1112 or (719) 457-0820, confirmation code 9942874. Today's conference call also will be webcast and can be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to
bring innovative drugs to patients with unmet m
|SOURCE Human Genome Sciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved